Prof. Meissner is Director of the Department of Neurology for Neurodegenerative Diseases at the University Hospital Bordeaux, Co-chair of the French Reference Center for Multiple System Atrophy (MSA) and Deputy Director of the Institute for Neurodegenerative Disease, CNRS UMR5293, University Bordeaux. He received his medical degree in 1997 from Humboldt University Berlin in Germany and his Board Certification in Neurology in 2005 after completing his residency at the Charité University Hospital in Berlin and the University Hospital Bordeaux. In 2005, he was awarded a PhD in Neuroscience at the University Bordeaux. He was appointed Professor of Neurology at the University Bordeaux in 2012. His current research focuses on biological and clinical markers of disease progression in Parkinson's disease (PD) and MSA, as well as the development of new preclinical models and treatments for these disorders in a translational approach. Within his current research activities, Prof. Meissner is particularly interested in the characterization of abnormal insulin/IGF-1 signalling in PD and MSA, has recently completed a phase 1 trial with two vaccines directed against alpha-synuclein in MSA patients within the framework of the European SYMPATH consortium and has coordinated the European ARTEMIS consortium aiming at the validation of several strategies targeting alpha-synuclein in preclinical models of MSA.